Abstract

Subanesthetic ketamine is increasingly used for the treatment of varied psychiatric conditions, both on- and off-label. While it is commonly classified as an N-methyl D-aspartate receptor (NMDAR) antagonist, our picture of ketamine’s mechanistic underpinnings is incomplete. Recent clinical evidence has indicated, controversially, that a component of the efficacy of subanesthetic ketamine may be opioid dependent. Using pharmacological functional ultrasound imaging in rats, we found that blocking opioid receptors suppressed neurophysiologic changes evoked by ketamine, but not by a more selective NMDAR antagonist, in limbic regions implicated in the pathophysiology of depression and in reward processing. Importantly, this opioid-dependent response was strongly sex-dependent, as it was not evident in female subjects and was fully reversed by surgical removal of the male gonads. We observed similar sex-dependent effects of opioid blockade affecting ketamine-evoked postsynaptic density and behavioral sensitization, as well as in opioid blockade-induced changes in opioid receptor density. Together, these results underscore the potential for ketamine to induce its affective responses via opioid signaling, and indicate that this opioid dependence may be strongly influenced by subject sex. These factors should be more directly assessed in future clinical trials.

In rats, functional ultrasound imaging reveals that blocking opioid receptors modulates the effects of subanesthetic ketamine on neural activity in males but not in females, with parallel changes in ketamine’s effects on brain structure and behavior.

Details

Title
Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats
Author
Di Ianni, Tommaso 1   VIAFID ORCID Logo  ; Ewbank, Sedona N. 2   VIAFID ORCID Logo  ; Levinstein, Marjorie R. 3   VIAFID ORCID Logo  ; Azadian, Matine M. 2   VIAFID ORCID Logo  ; Budinich, Reece C. 3 ; Michaelides, Michael 4   VIAFID ORCID Logo  ; Airan, Raag D. 5   VIAFID ORCID Logo 

 Stanford University School of Medicine, Department of Radiology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); University of California, San Francisco, Departments of Psychiatry & Behavioral Sciences and Radiology & Biomedical Imaging, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 Stanford University School of Medicine, Department of Radiology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
 National Institute on Drug Abuse Intramural Research Program, Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, Baltimore, USA (GRID:grid.420090.f) (ISNI:0000 0004 0533 7147) 
 National Institute on Drug Abuse Intramural Research Program, Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, Baltimore, USA (GRID:grid.420090.f) (ISNI:0000 0004 0533 7147); Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 Stanford University School of Medicine, Department of Radiology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University School of Medicine, Department of Materials Science and Engineering, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
Pages
893
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2919972856
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.